Safety and comparative immunogenicity of an HIV-1 DNA vaccine in combination with plasmid interleukin 12 and impact of intramuscular electroporation for delivery
about
DNA immunization as a technology platform for monoclonal antibody inductionCan follicular helper T cells be targeted to improve vaccine efficacy?HIV-Host Interactions: Implications for Vaccine DesignDNA and protein co-immunization improves the magnitude and longevity of humoral immune responses in macaquesIntramuscular delivery of heterodimeric IL-15 DNA in macaques produces systemic levels of bioactive cytokine inducing proliferation of NK and T cellsProtective immunity to H7N9 influenza viruses elicited by synthetic DNA vaccine.Developments in HIV-1 immunotherapy and therapeutic vaccination.Molecular mechanisms for enhanced DNA vaccine immunogenicity.An Enhanced Synthetic Multiclade DNA Prime Induces Improved Cross-Clade-Reactive Functional Antibodies when Combined with an Adjuvanted Protein Boost in Nonhuman Primates.Alarmin IL-33 elicits potent TB-specific cell-mediated responses.High-throughput flow cytometry data normalization for clinical trials.OpenCyto: an open source infrastructure for scalable, robust, reproducible, and automated, end-to-end flow cytometry data analysisA multi-head intradermal electroporation device allows for tailored and increased dose DNA vaccine delivery to the skinVaccination with Gag, Vif, and Nef gene fragments affords partial control of viral replication after mucosal challenge with SIVmac239Alarmin IL-33 acts as an immunoadjuvant to enhance antigen-specific tumor immunityThe influence of delivery vectors on HIV vaccine efficacyDNA vaccination by intradermal electroporation induces long-lasting immune responses in rhesus macaques.An optimized, synthetic DNA vaccine encoding the toxin A and toxin B receptor binding domains of Clostridium difficile induces protective antibody responses in vivoStrong HCV NS3/4a, NS4b, NS5a, NS5b-specific cellular immune responses induced in Rhesus macaques by a novel HCV genotype 1a/1b consensus DNA vaccine.Clearance of persistent HPV infection and cervical lesion by therapeutic DNA vaccine in CIN3 patients.Safety and preliminary evidence of biologic efficacy of a mammaglobin-a DNA vaccine in patients with stable metastatic breast cancerSafety Profile of the Merck Human Immunodeficiency Virus-1 Clade B gag DNA Plasmid Vaccine With and Without Adjuvants.HIV-1 Env DNA vaccine plus protein boost delivered by EP expands B- and T-cell responses and neutralizing phenotype in vivoSynthetic consensus HIV-1 DNA induces potent cellular immune responses and synthesis of granzyme B, perforin in HIV infected individualsMultiple factors affect immunogenicity of DNA plasmid HIV vaccines in human clinical trials.HIV-DNA Given with or without Intradermal Electroporation Is Safe and Highly Immunogenic in Healthy Swedish HIV-1 DNA/MVA Vaccinees: A Phase I Randomized Trial.A Phase I Double Blind, Placebo-Controlled, Randomized Study of the Safety and Immunogenicity of Electroporated HIV DNA with or without Interleukin 12 in Prime-Boost Combinations with an Ad35 HIV Vaccine in Healthy HIV-Seronegative African Adults.HIV DNA Vaccine: Stepwise Improvements Make a Difference.Co-Administration of Molecular Adjuvants Expressing NF-Kappa B Subunit p65/RelA or Type-1 Transactivator T-bet Enhance Antigen Specific DNA Vaccine-Induced Immunity.Early CD4+ T Cell Responses Are Associated with Subsequent CD8+ T Cell Responses to an rAd5-Based Prophylactic Prime-Boost HIV Vaccine StrategyTuberculosis vaccine development: Shifting focus amid increasing development challenges.Dose-dependent inhibition of Gag cellular immunity by Env in SIV/HIV DNA vaccinated macaquesDNA is an efficient booster of dendritic cell-based vaccineChemokine-adjuvanted electroporated DNA vaccine induces substantial protection from simian immunodeficiency virus vaginal challengeSuccessive site translocating inoculation potentiates DNA/recombinant vaccinia vaccinationThe Safety and Immunogenicity of an Interleukin-12-Enhanced Multiantigen DNA Vaccine Delivered by Electroporation for the Treatment of HIV-1 InfectionSafety, efficacy, and immunogenicity of VGX-3100, a therapeutic synthetic DNA vaccine targeting human papillomavirus 16 and 18 E6 and E7 proteins for cervical intraepithelial neoplasia 2/3: a randomised, double-blind, placebo-controlled phase 2b triMultivalent TB vaccines targeting the esx gene family generate potent and broad cell-mediated immune responses superior to BCG.Broad HIV-1 inhibition in vitro by vaccine-elicited CD8(+) T cells in African adults.Synthetic DNA vaccines: improved vaccine potency by electroporation and co-delivered genetic adjuvants.
P2860
Q26751432-A180577E-18B5-45BC-A4D5-097E209AD62AQ26753848-C7EBE16F-66F0-4AEE-BE60-7D5BAB08CBDFQ26765966-63A96662-59EB-462E-AFDE-D3482E253623Q27316075-186C48C1-D4C1-48B3-AF75-1A206C083E74Q28652428-883A2FBF-130D-4AFC-829D-D3E26250A2CDQ30360232-54C06365-9840-4D13-A838-CF2D96C7B8B9Q30364312-33A49B71-CDDD-4DA5-940F-5ABBA59A4768Q30366743-85B6D6E1-8923-4E72-8318-0A8E6D8FFA39Q30375785-4D8DCB2C-BDD2-4ED8-8329-896E282D8C6DQ30375869-3003DF15-41FD-4ED5-96A1-47DF1273F071Q30725027-CD3A21CA-BFA3-44E3-9099-535E8863B88EQ30845743-1F13D03F-E93C-462D-8CFA-7BF32231A9E5Q33723334-BAA52222-508C-47AD-9925-F26C7FD2544DQ33744109-21EB9A1D-F059-4683-93F3-57F54D68F3A2Q34033407-3F9FB8B7-266A-47DC-B7FB-4A3772D37727Q34077543-3AB933AE-33CE-4329-8650-ED6A19E4EFFBQ34250318-DBBF7FDB-E8D1-45AA-BED5-BB465704D728Q34298763-5DF7C693-C21E-49A9-990D-C05863CF1614Q34449537-A0B5B6BC-890E-4870-83AF-7F411B65DE45Q34453827-31245927-DAC7-44C2-881F-BA6AECCE285FQ35065923-0C38ABB9-7495-46BC-B4E3-406BB2DCFFFEQ35071969-54B688A2-D805-4CFA-A02B-EBD54BC40F33Q35082880-7079EDA2-B7CA-4491-A751-90688622AC44Q35153129-D892E03B-F80F-4B60-A49A-90BF92851597Q35611969-DB55B7BC-EC42-44CD-A6FA-D8BFD9268208Q35677513-7496F950-56A3-4786-82B9-70D5204D6103Q35739841-FF178CB7-F879-431B-8817-5FDC37D33B2AQ35826742-470113CD-3EAB-4C63-B462-6516D7E85002Q35826774-E26912C3-7D62-42FB-A35C-18E715005FD4Q36002028-0573B9DE-773D-4561-AD20-45929E624594Q36256304-614956ED-3B05-4F59-A055-B28A3C2BE1D5Q36256319-142B3CC4-91BB-4D4C-B349-0C433889694DQ36256389-27E1E9DA-6EAF-4FF5-9FB9-B8D42546135EQ36258203-9BBC46C4-6BE7-4F23-813B-216A0AE2909FQ36369631-C93529C0-3A36-493A-9E24-DB02B9D84271Q36462210-D0E5A3A9-74E7-4C41-B125-425EC0757734Q36954152-68521DB5-8D5E-4278-9741-450CD7DC6C74Q36978363-F10768DC-3337-4829-A28D-0CF77F406578Q37221660-24CB52A1-71C2-4F3A-8542-B122182186F9Q37276912-D7AB3BE2-7F4F-4272-8A0B-F6F598693A67
P2860
Safety and comparative immunogenicity of an HIV-1 DNA vaccine in combination with plasmid interleukin 12 and impact of intramuscular electroporation for delivery
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on 08 July 2013
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
Safety and comparative immunog ...... r electroporation for delivery
@en
Safety and comparative immunog ...... electroporation for delivery.
@nl
type
label
Safety and comparative immunog ...... r electroporation for delivery
@en
Safety and comparative immunog ...... electroporation for delivery.
@nl
prefLabel
Safety and comparative immunog ...... r electroporation for delivery
@en
Safety and comparative immunog ...... electroporation for delivery.
@nl
P2093
P2860
P50
P921
P356
P1476
Safety and comparative immunog ...... r electroporation for delivery
@en
P2093
Adam Sherwat
Amir S Khan
Barbara Metch
Chris Butler
David B Weiner
Denny H Kim
Donald K Carter
James G Kublin
Jean Boyer
P2860
P304
P356
10.1093/INFDIS/JIT236
P407
P577
2013-07-08T00:00:00Z